Stryker Corporation
SYK
$319.87
-3.42%
Stryker Corporation is a leading medical technology company that designs, manufactures, and markets a broad portfolio of medical equipment, instruments, consumable supplies, and implantable devices, primarily serving the orthopedic and surgical markets. As one of the three largest competitors in reconstructive orthopedic implants and the leader in operating room equipment, Stryker holds a dominant position in its industry. The current investor narrative centers on the company's ability to sustain growth through innovation and strategic acquisitions, such as the recent purchase of Amplitude Vascular Systems, while navigating a challenging macroeconomic environment that has pressured the stock price. Debate remains focused on margin expansion potential and the pace of recovery in elective procedure volumes.…
SYK
Stryker Corporation
$319.87
Related headlines
SYK 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Stryker Corporation's 12-month outlook, with a consensus price target around $386.52 and implied upside of +20.8% versus the current price.
Average Target
$386.52
0 analysts
Implied Upside
+20.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$315 - $465
Analyst target range
Stryker is covered by 25 analysts, with a consensus recommendation of 'Buy' (mean rating 1.63 on a 1-5 scale). The average target price is $386.52, implying approximately 20.8% upside from the current price of $319.87. The distribution leans bullish, with no sell ratings in the recent institutional ratings data. The target range spans from a low of $315.00 to a high of $465.00. The high target of $465.00 assumes strong growth acceleration and margin expansion, potentially driven by new product launches and acquisitions. The low target of $315.00 reflects risks such as competitive pressures or slower procedure volumes. Recent upgrades from BMO Capital (to Outperform) and consistent Outperform ratings from Evercore ISI and Leerink Partners indicate positive sentiment. The spread between low and high targets is $150, or 47% of the current price, signaling moderate uncertainty. Overall, the analyst consensus is bullish, with a clear upside bias.
Drowning in data?
Find the real signal!
Bulls vs Bears: SYK Investment Factors
Stryker presents a mixed picture: strong market leadership and a reasonable forward valuation are offset by decelerating revenue growth and margin compression. The bull case rests on the forward P/E of 19.1x and analyst consensus of 20.8% upside, while the bear case highlights the trailing P/E of 41.4x and declining operating margins. The single most important tension is whether the company can re-accelerate revenue growth and stabilize margins; if it does, the stock could re-rate higher, but if not, further downside is possible. Currently, the evidence slightly favors the bulls given the attractive forward valuation and strong balance sheet, but margin trends warrant close monitoring.
Bullish
- Strong Analyst Consensus Buy: 25 analysts rate SYK a Buy with a mean target of $386.52, implying ~20.8% upside from $319.87. No sell ratings exist, reflecting broad institutional confidence.
- Forward P/E Compressed to 19.1x: The forward P/E of 19.13x is near the lower end of its historical range (24x-78x trailing) and offers a reasonable entry point for a market leader. This implies the market expects significant earnings growth.
- Dominant Market Position in Orthopedics: Stryker is one of the top three players in reconstructive orthopedic implants and the leader in operating room equipment. This competitive moat supports pricing power and recurring revenue.
- Healthy Balance Sheet and Cash Flow: Debt-to-equity of 0.73 and current ratio of 1.89 indicate low financial risk. TTM free cash flow of $4.57 billion provides ample liquidity for acquisitions and dividends.
Bearish
- Revenue Growth Deceleration: Q1 2026 revenue grew only 2.63% YoY, down from 7.2% in Q4 2025. This deceleration raises concerns about market saturation and competitive pressures.
- Margin Compression Pressuring Profits: Operating margin fell from 22.6% in Q2 2025 to 15.55% in Q1 2026, a decline of over 700 bps. Net margin also dropped from 14.68% to 12.38% over the same period.
- Elevated Trailing P/E of 41.4x: Despite the forward P/E being reasonable, the trailing P/E of 41.4x is high relative to the broader market. This leaves little room for error if earnings disappoint.
- Stock in Sustained Downtrend: SYK is down 17.75% over the past year and trades at 79% of its 52-week range. The stock has underperformed the S&P 500 by 36.1% over the same period, indicating persistent selling pressure.
SYK Technical Analysis
Stryker is in a sustained downtrend over the past year, with a 1-year price change of -17.75%. The current price of $319.87 sits at approximately 79% of its 52-week range (low $281.00, high $404.87), indicating the stock is closer to its lows than highs. This positioning suggests a potential value opportunity, but also reflects persistent selling pressure and a lack of bullish momentum. Over the last month, the stock has gained 6.22%, while the 3-month change is -6.83%, showing a short-term bounce within a longer-term decline. This divergence between the 1-month and 1-year trends could signal a temporary pullback or the early stages of a reversal, but the 3-month negative performance suggests caution. The stock's beta of 0.778 indicates it is less volatile than the market, which may appeal to risk-averse investors but also limits upside in strong market rallies. The 52-week low of $281.00 provides key support, while the high of $404.87 is a major resistance level. A breakout above $404.87 would signal a strong reversal, while a breakdown below $281.00 could accelerate losses. The stock's lower beta suggests it may not participate fully in market upswings, which is important for position sizing.
Beta
0.78
0.78x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$281-$405
Price range past year
Annual Return
-17.8%
Cumulative gain past year
| Period | SYK Return | S&P 500 |
|---|---|---|
| 1m | +6.2% | -0.5% |
| 3m | -6.8% | +4.9% |
| 6m | -12.1% | +9.7% |
| 1y | -17.8% | +18.4% |
| ytd | -8.1% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SYK Fundamental Analysis
Stryker's revenue trajectory shows steady but decelerating growth. In Q1 2026, revenue was $6.02 billion, up 2.63% year-over-year, compared to 7.2% growth in Q4 2025. The MedSurg segment contributed $3.207 billion and Orthopaedics $2.813 billion, indicating balanced performance across divisions. The deceleration in growth raises questions about the company's ability to maintain momentum, though the recent acquisition of Amplitude Vascular Systems could provide a catalyst. The company is profitable, with net income of $745 million in Q1 2026 and a gross margin of 63.29%. However, the net margin of 12.38% is lower than the 14.68% in Q2 2025, suggesting margin compression. Operating margin was 15.55% in Q1 2026, down from 22.60% in Q2 2025, indicating rising costs or mix shifts. Stryker maintains a healthy balance sheet with a debt-to-equity ratio of 0.73 and a current ratio of 1.89. Free cash flow was $415 million in Q1 2026, down from $1.875 billion in Q4 2025, but the trailing twelve-month FCF of $4.571 billion provides ample liquidity. ROE of 14.48% is solid, indicating efficient use of equity.
Quarterly Revenue
$6.0B
2026-03
Revenue YoY Growth
+2.6%
YoY Comparison
Gross Margin
63.3%
Latest Quarter
Free Cash Flow
$4.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SYK Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 41.40x, while the forward P/E is 19.13x, implying the market expects significant earnings growth. The wide gap between trailing and forward multiples suggests optimism about future profitability. Compared to the industry average (not provided), Stryker's P/E of 41.40x appears elevated, but the forward P/E of 19.13x is more reasonable. The PEG ratio of 5.16x indicates the stock is priced for high growth, which may be justified by its market leadership and innovation pipeline. Historically, Stryker's trailing P/E has ranged from around 24x to 78x over the past few years. The current 41.40x is near the middle of this range, suggesting it is not excessively overvalued or undervalued relative to its own history. The P/S ratio of 5.35x is also within historical norms, supporting a neutral valuation stance.
PE
41.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 38x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Stryker's primary financial risk is margin compression, with operating margin declining from 22.6% in Q2 2025 to 15.55% in Q1 2026, a drop of over 700 bps. This pressure stems from rising costs (SG&A up to $2.28B in Q1 2026 from $1.99B in Q2 2025) and a shift in product mix. Additionally, revenue growth decelerated to 2.63% YoY in Q1 2026, down from 7.2% in Q4 2025, raising concerns about top-line momentum. The company's debt-to-equity of 0.73 is manageable, but interest expense of $148M in Q1 2026 adds to fixed costs. Free cash flow of $415M in Q1 2026 was down sharply from $1.875B in Q4 2025, though TTM FCF remains robust at $4.57B.
Market & Competitive Risks: Stryker faces valuation risk with a trailing P/E of 41.4x, which is elevated relative to the market and leaves limited upside if earnings disappoint. The stock's beta of 0.778 indicates lower market correlation, but it has underperformed the S&P 500 by 36.1% over the past year, suggesting sector-specific headwinds. Competitive threats include Boston Scientific and other med-tech firms, though Stryker's leadership in orthopedics and OR equipment provides a buffer. Regulatory risks are inherent in the medical device industry, and the recent acquisition of Amplitude Vascular Systems introduces integration risk.
Worst-Case Scenario: In a severe downturn, Stryker could see its stock fall to the 52-week low of $281.00, representing a 12.2% decline from the current price of $319.87. This scenario could be triggered by continued margin erosion, a recession reducing elective procedures, or a failed product launch. The analyst low target of $315.00 is only 1.5% below the current price, implying limited downside in the base case, but the 52-week low provides a more conservative floor. Historical max drawdown of -29.97% suggests a potential decline to ~$224, though this is less likely given the company's fundamentals.
